FRANKLIN LAKES, N.J.,
April 27, 2018 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced three executive
appointments to the positions of segment president.
Alberto Mas, 56, has been named
president of the Medical Segment for BD, effective May 29, reporting to Tom
Polen, president of BD. For the past two years, Mas has held
the role of president of the Life Sciences Segment for BD, and
prior to that served as president of three major business units
including Diagnostic Systems, Biosciences and Medical Surgical
Systems (now known as Medication Delivery Solutions).
"Alberto is a proven leader who has excelled at every position
he's held at BD," Polen said. "He is the right leader for our
largest segment, and I have full confidence he will continue to
drive our growth and innovation strategy across the Medical
Segment."
Patrick Kaltenbach, 54, has been
named president of the Life Sciences Segment for BD, replacing Mas
and reporting to Polen, effective May
29. Kaltenbach has served as senior vice president of
Agilent and president of the Life Sciences and Applied Markets
Group (LSAG) since 2014. He joined Agilent's predecessor,
Hewlett-Packard Co., in 1991 as a research and development
(R&D) engineer in the Capillary Electrophoresis business. Over
the years, he has held various roles in R&D management and
business leadership. Kaltenbach holds a degree in precision
engineering from the Karlsruhe
University of Applied Science in Germany.
"Attracting an industry leader of Patrick's caliber to BD is a
testament to our life sciences strategy and the segment's progress
toward becoming a transformative partner from discovery to
diagnosis," Polen said. "Patrick brings a unique combination of
deep experience and knowledge within the life sciences industry and
a passion for creating value through innovation and technology. We
are pleased to have his leadership as we continue to advance our
Life Sciences Segment."
In addition, the company named Bill
Tozzi, 62, as interim president of the Interventional
Segment for BD, also reporting to Polen and effective May 1. Tozzi has been serving as the integration
leader for the C. R. Bard transaction since April 2017. Prior to his role as integration
leader, Tozzi served as the president of Medication and Procedural
Solutions (now known as Medication Delivery Solutions) for six
years. John Groetelaars, who has
been serving as the president of the Interventional Segment for BD
since the completion of the Bard transaction, has decided to leave
BD for an executive position at another company.
"Bill is a seasoned BD executive with a strong track record of
success and deep integration experience," Polen added. "Together
with the strong Interventional Segment leadership team driving the
business, I am confident we are well positioned to fulfill our
potential as a combined company. I would also like to thank John
for his dedication and leadership to Bard and BD. I know that
everyone at BD wishes him much success in the next chapter of his
career."
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 65,000 employees have a passion and
commitment to help improve patient outcomes, improve the safety and
efficiency of clinicians' care delivery process, enable laboratory
scientists to better diagnose disease and advance researchers'
capabilities to develop the next generation of diagnostics and
therapeutics. BD has a presence in virtually every country and
partners with organizations around the world to address some of the
most challenging global health issues. By working in close
collaboration with customers, BD can help enhance outcomes, lower
costs, increase efficiencies, improve safety and expand access to
health care. In 2017, BD welcomed C. R. Bard and its products into
the BD family. For more information on BD, please visit bd.com.
Contacts:
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public Relations
|
BD
Investor
|
Relations858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-names-three-executives-to-segment-leadership-roles-300637799.html
SOURCE BD (Becton, Dickinson and Company)